Katy Spink, PhD
Katy Spink, Ph.D.is currently Chief Operating Officer and Managing Partner at Dark Horse Consulting Group, a global consulting practice specializing in the development of Cell and Gene Therapy products. Prior to joining Dark Horse, Dr. Spink was Chief Operating Officer of Asterias Biotherapeutics, a publicly-traded company with three clinical-stage cell therapy programs, from 2013 to 2018. Dr. Spink previously served as Senior Vice President of Alliance Management and Cell Therapy Program Operations at Geron Corporation, where she was employed in roles of increasing responsibility within the R&D and Business Development groups from 2003 through 2011. In this role, Dr. Spink served as the cross-functional Project Team Leader for Geron’s GRNCM1 cardiovascular cell therapy program from 2007 through 2011.
Prior to joining Geron, Dr. Spink was a management consultant at McKinsey & Company, advising clients in the biotechnology, pharmaceutical, and medical device industries on matters relating to R&D strategy, business development, and marketing. Dr. Spink graduated Magna Cum Laude and Phi Beta Kappa with a B.A. in Biochemistry from Rice University and received her Ph.D. in Cancer Biology from Stanford University as a Howard Hughes Predoctoral Fellow.
While members of the Medical Advisory Board are consulted to provide third party expert medical input into Triple-Gene’s product development efforts and clinical trial activities, they do not dictate or direct, nor are they responsible for, any development or clinical activities ultimately undertaken by Triple-Gene.